Vice President, Finance and Corporate Controller
Mr. Scott Peters joined Pliant Therapeutics as Vice President, Finance and Corporate Controller in February 2021 bringing close to 20 years of finance and accounting experience to the role. Prior to Pliant, Mr. Peters held roles of increasing responsibility at Portola Pharmaceuticals, now Alexion, where, over an 8-year period, he helped manage its evolution from a clinical late-stage organization to a multi-national, commercial-stage company, having most recently served as Executive Director and Corporate Controller. Prior to this, Mr. Peters held worldwide roles at KPMG LLP, one of the four largest professional accounting services networks in the world, where he managed an extensive array of accounting and auditing services for a wide range of differing size, stage of development and industry companies, including large cap pharmaceutical companies. Mr. Peters received his B.S. in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara.
Pliant is led by a team of world-renowned fibrosis researchers and highly experienced drug developers focused on translating science into novel therapies for patients in need.